Ali Behbahani

Ali is a general partner at New Enterprise Associates (NEA). Prior to NEA, he held positions at The Medicines Company, Morgan Stanley Venture Partners and Lehman Brothers. He has been a member of the Board of Directors of Genocea Biosciences, Oyster Point Pharma, CRISPR Therapeutics, Adaptimmune Therapeutics, Black Diamond Therapeutics, and was on the board of Nevro Corp. Ali received a B.S. from Duke University, an M.B.A. from the Wharton School of the University of Pennsylvania, and an M.D. from the University of Pennsylvania School of Medicine.